United States
United States

Time filter

Source Type

WiseGuyReports.Com Publish a New Market Research Report On –“Global 3D Medical Imaging Equipment Market 2016 Share,Trend,Segmentation and Forecast to 2021”. This report studies 3D Medical Imaging Equipment in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering  GE Healthcare  Hitachi Aloka Medical  Intrasense SA  Materialise NV  Philips Healthcare  Samsung Medison  Siemens Healthcare  The Esaote Group  TomTec Imaging Systems  Toshiba America Medica For more information or any query mail at [email protected] Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of 3D Medical Imaging Equipment in these regions, from 2011 to 2021 (forecast), like  North America  Europe  China  Japan  Southeast Asia  India Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into  MRI  CT  Ultrasound Machines  Other 3d Medical Imaging Equipments Split by application, this report focuses on consumption, market share and growth rate of 3D Medical Imaging Equipment in each application, can be divided into  Cardiovascular  Metabolic Disorders  Central Nervous System  Oncology  General Medical Imaging  Life Science Research  Other Applications Global 3D Medical Imaging Equipment Market Research Report 2016  1 3D Medical Imaging Equipment Market Overview  1.1 Product Overview and Scope of 3D Medical Imaging Equipment  1.2 3D Medical Imaging Equipment Segment by Type  1.2.1 Global Production Market Share of 3D Medical Imaging Equipment by Type in 2015  1.2.2 MRI  1.2.3 CT  1.2.4 Ultrasound Machines  1.2.5 Other 3d Medical Imaging Equipments  1.3 3D Medical Imaging Equipment Segment by Application  1.3.1 3D Medical Imaging Equipment Consumption Market Share by Application in 2015  1.3.2 Cardiovascular  1.3.3 Metabolic Disorders  1.3.4 Central Nervous System  1.3.5 Oncology  1.3.6 General Medical Imaging  1.3.7 Life Science Research  1.3.8 Other Applications  1.4 3D Medical Imaging Equipment Market by Region  1.4.1 North America Status and Prospect (2011-2021)  1.4.2 Europe Status and Prospect (2011-2021)  1.4.3 China Status and Prospect (2011-2021)  1.4.4 Japan Status and Prospect (2011-2021)  1.4.5 Southeast Asia Status and Prospect (2011-2021)  1.4.6 India Status and Prospect (2011-2021)  1.5 Global Market Size (Value) of 3D Medical Imaging Equipment (2011-2021) 2 Global 3D Medical Imaging Equipment Market Competition by Manufacturers  2.1 Global 3D Medical Imaging Equipment Production and Share by Manufacturers (2015 and 2016)  2.2 Global 3D Medical Imaging Equipment Revenue and Share by Manufacturers (2015 and 2016)  2.3 Global 3D Medical Imaging Equipment Average Price by Manufacturers (2015 and 2016)  2.4 Manufacturers 3D Medical Imaging Equipment Manufacturing Base Distribution, Sales Area and Product Type  2.5 3D Medical Imaging Equipment Market Competitive Situation and Trends  2.5.1 3D Medical Imaging Equipment Market Concentration Rate  2.5.2 3D Medical Imaging Equipment Market Share of Top 3 and Top 5 Manufacturers  2.5.3 Mergers & Acquisitions, Expansion 7 Global 3D Medical Imaging Equipment Manufacturers Profiles/Analysis  7.1 GE Healthcare  7.1.1 Company Basic Information, Manufacturing Base and Its Competitors  7.1.2 3D Medical Imaging Equipment Product Type, Application and Specification  7.1.2.1 Type I  7.1.2.2 Type II  7.1.3 GE Healthcare 3D Medical Imaging Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.1.4 Main Business/Business Overview  7.2 Hitachi Aloka Medical  7.2.1 Company Basic Information, Manufacturing Base and Its Competitors  7.2.2 3D Medical Imaging Equipment Product Type, Application and Specification  7.2.2.1 Type I  7.2.2.2 Type II  7.2.3 Hitachi Aloka Medical 3D Medical Imaging Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.2.4 Main Business/Business Overview  7.3 Intrasense SA  7.3.1 Company Basic Information, Manufacturing Base and Its Competitors  7.3.2 3D Medical Imaging Equipment Product Type, Application and Specification  7.3.2.1 Type I  7.3.2.2 Type II  7.3.3 Intrasense SA 3D Medical Imaging Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.3.4 Main Business/Business Overview  7.4 Materialise NV  7.4.1 Company Basic Information, Manufacturing Base and Its Competitors  7.4.2 3D Medical Imaging Equipment Product Type, Application and Specification  7.4.2.1 Type I  7.4.2.2 Type II  7.4.3 Materialise NV 3D Medical Imaging Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.4.4 Main Business/Business Overview  7.5 Philips Healthcare  7.5.1 Company Basic Information, Manufacturing Base and Its Competitors  7.5.2 3D Medical Imaging Equipment Product Type, Application and Specification  7.5.2.1 Type I  7.5.2.2 Type II  7.5.3 Philips Healthcare 3D Medical Imaging Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.5.4 Main Business/Business Overview  7.6 Samsung Medison  7.6.1 Company Basic Information, Manufacturing Base and Its Competitors  7.6.2 3D Medical Imaging Equipment Product Type, Application and Specification  7.6.2.1 Type I  7.6.2.2 Type II  7.6.3 Samsung Medison 3D Medical Imaging Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.6.4 Main Business/Business Overview  7.7 Siemens Healthcare  7.7.1 Company Basic Information, Manufacturing Base and Its Competitors  7.7.2 3D Medical Imaging Equipment Product Type, Application and Specification  7.7.2.1 Type I  7.7.2.2 Type II  7.7.3 Siemens Healthcare 3D Medical Imaging Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.7.4 Main Business/Business Overview  7.8 The Esaote Group  7.8.1 Company Basic Information, Manufacturing Base and Its Competitors  7.8.2 3D Medical Imaging Equipment Product Type, Application and Specification  7.8.2.1 Type I  7.8.2.2 Type II  7.8.3 The Esaote Group 3D Medical Imaging Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.8.4 Main Business/Business Overview  7.9 TomTec Imaging Systems  7.9.1 Company Basic Information, Manufacturing Base and Its Competitors  7.9.2 3D Medical Imaging Equipment Product Type, Application and Specification  7.9.2.1 Type I  7.9.2.2 Type II For more information or any query mail at [email protected] Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.


News Article | December 21, 2016
Site: www.eurekalert.org

Extra vitamin D can restore good bacteria in the gut, according to a study in mice, giving hope in the fight against risk factors for diabetes and heart disease It is well known that a diet high in fat can trigger a metabolic syndrome, a group of symptoms that pose as risk factors for diabetes and heart disease. Scientists have now discovered that vitamin D deficiency is necessary for this syndrome to progress in mice, with underlying disturbances in gut bacteria. If these findings can be validated in humans, sun bathing and vitamin D supplements may be feasible and affordable approaches to improve or even prevent metabolic syndrome. "Based on this study, we believe that keeping vitamin D levels high, either through sun exposure, diet or supplementation, is beneficial for prevention and treatment of metabolic syndrome," says Professor Stephen Pandol, at Cedars-Sinai Medical Center, USA, who collaborated with Yuan-Ping Han's research group at Sichuan University, China in the study. Metabolic syndrome affects nearly a quarter of the world's adult population, and it is defined by a group of risk factors that put you on the road to diabetes and heart disease. The characteristic symptoms include obesity around the waistline and at least two of the following: high blood sugar levels, high blood pressure or high cholesterol. Sufferers usually also have excess fat in their liver. The main cause of metabolic syndrome appears to be a diet high in fat or carbohydrate. However, observational studies have also linked metabolic syndrome to vitamin D deficiency, which affects 30-60% of the world's population. The research team made important advances in understanding the causative role of vitamin D in this syndrome. "A sufficient dietary vitamin D supplement can partially but significantly antagonize metabolic syndrome caused by high fat diet in mice," says Pandol. "These are amounts equivalent to the dietary recommendations for humans." More specifically, they have shown that a high fat diet affects the balance between good and bad bacteria in the gut. This induces modest fatty liver and slightly raises blood sugar levels in mice. Remarkably, an insufficient supply of vitamin D aggravates the imbalance in gut flora, contributing to full-scale fatty liver and metabolic syndrome. Vitamin D deficiency decreases the production of defensins, which are anti-microbial molecules essential to maintain healthy gut flora. As expected, an oral supply of a synthetic defensin recovers gut bacteria balance, decreases blood sugar levels and improves fatty liver. In summary, a high fat diet alone is not enough to cause metabolic syndrome but it is needed in combination with vitamin D deficiency. Accordingly, vitamin D supplementation improves metabolic syndrome in mice. The next step would be to validate the results in humans. "Few studies have indicated that vitamin D supplementation may not improve metabolic disorders in humans. However, these studies are largely based on long-term surveys, which may be hampered by poor compliance and insufficient dosage," says Hans. He remains optimistic that the results of their study can be confirmed in humans. "We are planning a clinical study to confirm the link of vitamin D deficiency with gut bacteria disruption, and its association with metabolic syndrome," says Han. The study was supported by grants from National Natural Science Foundation of China (31571165), and Science and Technology Department of Sichuan Province (2014SZ0194) to YH, NIH R01 AA019954 P01 CA163200 (AL, SP). Department of Veterans Affairs grants: 5IO BX001991-02F (HT), and I01BX001484 (SP). Read the full article in Frontiers in Physiology: 'Vitamin D Signaling through Induction of Paneth Cell Defensins Maintains Gut Microbiota and Improves Metabolic Disorders and Hepatic Steatosis in Animal Models'


Research and Markets has announced the addition of the "Global Apheresis Equipment Market Analysis & Trends - Industry Forecast to 2025" report to their offering. The Global Apheresis Equipment Market is poised to grow at a CAGR of around 12.3% over the next decade to reach approximately $4.5 billion by 2025. This industry report analyzes the market estimates and forecasts for all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors. Some of the trends viewed by the market are increase in therapeutic apheresis and treatment of cancer, rise in the number of platelet donors & plasma donations, rising incidence rates of genetic disorders such as sickle cell anemia and growth Opportunities/Investment Opportunities. On the basis of technology, market is bifurcated into Membrane Filtration and Centrifugation. The Centrifugation segment is further subdivided into Continuous Flow and Intermittent Flow. Based on procedure, the market is categorized into Erythrocytapheresis, Extracorporeal Immunoadsorption (ECI), Leukapheresis, Plasmapheresis, Photopheresis, Low Density Lipoprotein (LDL) Apheresis, Plateletpheresis, Therapeutic CytApheresis Equipment and Other Procedures. Other Procedures segment is subdivided into Lipidpheresis and Lymphapheresis. Depending on application, the market is segregated into Hematology, Neurological Disorders, Renal Disorders, Metabolic Disorders, Autoimmune Disorders, Cardiovascular Disorders and Other Applications. Depending on product, the market is divided into Apheresis machine and Disposable apheresis kits - The report provides a detailed analysis on current and future market trends to identify the investment opportunities - Market forecasts till 2025, using estimated market values as the base numbers - Key market trends across the business segments, Regions and Countries - Key developments and strategies observed in the market - Market Dynamics such as Drivers, Restraints, Opportunities and other trends - Growth prospects among the emerging nations through 2025 - Market opportunities and recommendations for new investments For more information about this report visit http://www.researchandmarkets.com/research/2fd5tv/global_apheresis


News Article | February 23, 2017
Site: www.eurekalert.org

Is a tool that makes it possible to monitor metabolic fluxes and, in 10 minutes, provide dynamic information about a considerable number of molecules. It may be able to be used in future applications to understand the reasons why some diseases develop If we were to take photographs at the underground stations in Barcelona, we would see the number of people waiting, find out what time the rush hour takes place and deduce why some stations are busier than others. We would not know, however, if something has happened between one station and another that has led to more people being on the platforms or that might have caused delays. This is what happens when the metabolism of a cell is studied. The metabolism of a cell is like an underground network in which the chemical structures of the metabolites go from one station to another by means of biochemical transformations. Up until now, it has been possible to determine the number of many metabolites in a cell, tissue or organism, but studying their fluxes is technically much more complex and time consuming. Now, however, a group of researchers from the URV, CIBERDEM and IRB Barcelona have developed a new tool that makes this possible. The nuclear magnetic resonance (NMR) techniques used to date covered very few metabolites, researchers could take hours to measure every sample and the data were difficult to interpret. The new approach is very quick - 10 minutes per sample -, many more metabolites are obtained and the results are much easier to interpret. That is to say, the movements made by the metabolism can be determined much more easily and effectively. It is a methodology based on NMR which measures hydrogen atoms (protons) in order to indirectly determine the number of carbon atoms that are marked in the chemical structures of the metabolites. The experiment is as follows: a nutrient is marked that the cells feed on, like glucose or aminoacids, with a stable isotope. Stable isotopes such as carbon 13 are not radioactive and do not represent any danger to organisms or the people who handle the samples. The proton is measured by NMR much more quickly and sensitively than the carbon and, in this way, it is possible to study the fluxes and the transformation dynamics of these nutrients inside the cell. So far the efficacy of this new technique has been validated using human cancer cells but it is directly applicable to any biological model. Diabetes, for example, is a metabolic syndrome in which the process begins long before the levels of glucose in the blood increase, because the body uses a variety of mechanisms to ensure that the concentration of this nutrient remains stable. And high levels of glucose are only seen in the blood when the disease is at an advanced stage. The technique that has just been reported describes a new way of studying the mechanisms that cause some tissues in the organism (for example, liver or pancreas cells) not to be able to regulate levels of glucose or to become insensitive to it. That is to say, the study of metabolic fluxes helps us understand the reasons why the disease develops and the mechanism by which it does so. Therefore, it also helps in the process of diagnosis. In short, it is a methodology with great potential that practising physicians and molecular biologists will be able to use to acquire greater understanding of certain diseases. The new technique, unlike more traditional techniques, does not use radioactivity to study the metabolism. The article, which has been published in the scientific journal Angewandte Chemie, shows the results of this work on cancer cells, but the researchers are sure that glucose, aminoacids and fats marked with stable isotopes can be found in other cells and even animals. The fact that they are not radioactive makes them much easier to work with because there is no need for special laboratory conditions. In their work, the researchers have used NMR quite differently from how it has traditionally been used to study the metabolism. Maria Vinaixa, a researcher from the URV's Department of Electronic Engineering and currently carrying out research at the University of Manchester, and Oscar Yanes, a researcher from the same URV department and coordinator of the Metabolomic Platform of the Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), explain that with this methodology "we exploit to the full the power of nuclear magnetic resonance in terms of its sensitivity and coverage of the metabolism," and they believe that "it is difficult to take it any further". Now the limitation is the resonance itself. Vinaixa, M., Rodríguez, M. A., Aivio, S., Capellades, J., Gomez, J., Canyellas, N., Stracker, T. H. and Yanes, O. (2017), "Positional Enrichment by Proton Analysis (PEPA): A One-Dimensional 1H-NMR Approach for 13C Stable Isotope Tracer Studies in Metabolomics". Angew. Chem. Int. Ed. doi:10.1002/anie.201611347


TEL AVIV, Israel, March 02, 2017 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), a developer of stem cells isolation technology, today announced the appointment of Dr. Michael Berelowitz to the Company’s Board of Directors. Cellect’s Board now includes seven members, five of whom are independent. Dr. Berelowitz is a former Head of Clinical Development and Medical Affairs at Pfizer and brings over 40 years of clinical, development and academic research experience. Prior to Pfizer, he spent a number of years in academia and has held appointments at the University of Chicago, University of Cincinnati College of Medicine, SUNY at Stony Brook and most recently, Mount Sinai School of Medicine. Commenting on his appointment, Dr. Berelowitz, said: “Cellect is a unique company with strong potential to become a major influencer in the future of regenerative medicine. I have always supported front-runners and I am happy to be a part of Cellect’s team on this journey.” Cellect’s Chairman of the Board, Nuriel Chirich Kasbian, said: “It is key that we construct the strongest board possible to help Cellect rise above its challenges. Dr. Berelowitz is a true asset to our company and its future growth. I welcome him to our board of directors.” Among his many accomplishments, Dr. Berelowitz has chaired the Task Force on Research of the New York State Council on Diabetes. He has also served on several editorial boards including the Journal of Clinical Endocrinology and Metabolism; Endocrinology; Reviews in Endocrine and Metabolic Disorders and Clinical Diabetes. Dr. Berelowitz has authored and co-authored more than 100 peer-reviewed journal articles and book chapters. Cellect Biotechnology is traded on both the NASDAQ and Tel Aviv Stock Exchange (NASDAQ:APOP) (NASDAQ:APOPW) (TASE:APOP). The Company has developed a breakthrough technology for the isolation of stem cells from any given tissue that aims to improve a variety of stem cells applications. The Company’s technology is expected to provide pharma companies, medical research centers and hospitals with the tools to rapidly isolate stem cells in quantity and quality that will allow stems cell related treatments and procedures. Cellect’s technology is applicable to a wide variety of stem cells related treatments in regenerative medicine and that current clinical trials are aimed at the cancer treatment of bone marrow transplantations. Forward Looking Statements     This press release contains forward-looking statements about the Company’s expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect having a strong potential to become a major influencer in the future of regenerative medicine, that Cellect has developed a breakthrough technology for the isolation of stem cells from any given tissue and that Cellect’s technology is expected to provide pharma companies, medical research centers and hospitals with the tools to rapidly isolate stem cells in quantity and quality that will allow stems cell related treatments and procedures. These forward-looking statements and their implications are based on the current expectations of the management of the Company only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in Cellect Biotechnology Ltd.'s final prospectus dated July 29, 2016 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov. and in the Company’s period filings with the SEC and the Tel-Aviv Stock Exchange.


News Article | November 14, 2016
Site: www.newsmaker.com.au

Type 2 diabetes is a chronic condition and is the most common form of diabetes. High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits and various other effects. Risk factors include family history, age, obesity, physical inactivity and high blood pressure. This condition is handled by lifestyle alterations and regular medications. Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 18, 25, 71, 54, 6, 252, 85 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 66 and 20 molecules, respectively.Type 2 Diabetes. Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. - The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


News Article | November 13, 2016
Site: www.newsmaker.com.au

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis – Pipeline Review, H2 2016, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape. Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues. Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post Menopausal Osteoporosis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 5, 1, 1 and 6 respectively for Post Menopausal Osteoporosis. Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. - The pipeline guide provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders) - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. FOR ANY QUERY, REACH US @ Post Menopausal Osteoporosis - Pipeline Review, H2 2016


News Article | November 16, 2016
Site: www.newsmaker.com.au

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis – Pipeline Review, H2 2016, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape. Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications. Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 4, 8, 14, 1, 54 and 10 respectively for  Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 8 and 13 molecules, respectively for Osteoporosis. Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. - The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders) - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. FOR ANY QUERY, REACH US @ https://www.wiseguyreports.com/enquiry/731593-osteoporosis-pipeline-review-h2-2016


News Article | November 13, 2016
Site: www.newsmaker.com.au

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ageing – Pipeline Review, H2 2016, provides an overview of the Ageing (Metabolic Disorders) pipeline landscape. Ageing is the accumulation of changes in a person over time. Symptoms include stooped posture, constipation, and increased susceptibility to infection, risk of heat stroke or hypothermia, decrease in visual acuity, wrinkling and sagging skin, and diminished peripheral vision. Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ageing – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ageing (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Ageing (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ageing and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 5 and 3 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively for Ageing. Ageing (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. - The pipeline guide provides a snapshot of the global therapeutic landscape of Ageing (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Ageing (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Ageing (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Ageing (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Ageing (Metabolic Disorders) - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Ageing (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Ageing (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. FOR ANY QUERY, REACH US @ Ageing - Pipeline Review, H2 2016


News Article | November 10, 2016
Site: www.prnewswire.co.uk

According to the new market research report, "Molecular Diagnostics Market, by Products (Instruments & Systems and Reagents & Consumables), Applications (Infectious Diseases, Blood Screening, Histology, Oncology, Prenatal, Coagulation, Tissue Typing, Inherited Diseases, Genetic Testing and Pharmacogenomics), Technologies (DNA Sequencing, PCR Microarray and Fluorescent In Situ Hybridization) - Global Revenue, Trends, Growth, Share, Size and Forecast to 2022", published by Scalar Market Research, the global molecular diagnostics market is expected to grow from USD 5.44 billion in 2014 and become worth USD 11.04 billion by 2022, growing at a CAGR of 9.3% from 2014 to 2022. The global molecular diagnostics market report offers in-depth analysis of the market size (revenue), market share, major market segments, different geographic regions, key players, premium trends and forecast to 2022. It also focuses on the key drivers and opportunities in this market. Buyers can expect to receive 100% customization on this report. North America is projected to dominate the molecular diagnostics market According to the report, the North America region is expected to hold the largest share in the global molecular diagnostics market during the forecast period. The strong awareness towards healthcare and the rising prevalence of the chronic diseases are some of the major contributing factors to the stronghold of the North America region over the global market. The report expects that Asia-Pacific will be the fastest-growing geographic region in the market during the forecast period. The key players highlighted in the molecular diagnostics market report include: Dermatology Devices Market, by Diagnostic Devices (Dermatoscopes, Microscopes, Imaging Techniques), Treatment Devices (Liposuction, Microdermabrasion, Cryotherapy, Electrosurgical, Light Therapy Devices, Lasers), Applications (Cancer Diagnosis, Wrinkle Removal, Skin Rejuvenation, Skin Resurfacing, Vascular Lesions, Acne, Psoriasis, Hair Removal) - Global Revenue, Trends, Growth, Share, Size and Forecast to 2022 Prescription Pharmaceuticals Market, by Therapeutic Segments (Cardiovascular Disorders, Inflammatory Conditions, Metabolic Disorders, Oncology, Respiratory Disorders, Others), Formulations (Capsules, Inhalants, Parenterals, Tablets, Topicals) - Global Revenue, Trends, Growth, Share, Size and Forecast to 2020 Scalar Market Research, Inc. is a Chicago, U.S.-based market research and consulting firm that serves Fortune 1000 companies, leading businesses and upcoming organizations from around the world to help them achieve their business goal of sustainable revenue growth, utilizing Scalar's premium market research reports and consulting services to make critical strategic decisions. Our real-time industry data tracking, with the help of advanced analytics and machine learning, offers our clients highly accurate 360-degree perspective of key developments in niche markets. Our team of industry experts, with a thorough understanding of global markets and cumulative industry experience spanning 100+ years, work relentlessly to help our clients realize their most important business goals. Find out more about our services at: www.scalarmarketresearch.com

Loading Metabolic Disorders collaborators
Loading Metabolic Disorders collaborators